Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205689 | 0.92 | USP30 (0.54) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| SCHEMBL23602645 | 0.92 | USP30 (0.54) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| SCHEMBL10165886 | 0.92 | USP30 (0.54) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| SCHEMBL10165816 | 0.91 | EPHX1 (0.65) | EPHX1PARP1HDAC4ALDH1A1 | |
| SCHEMBL4500835 | 0.91 | EPHX1 (0.54) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| Hydrochloric Acid SCHEMBL2490701 | 0.91 | USP30 (0.53) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| Hydrochloric Acid SCHEMBL2490699 | 0.91 | USP30 (0.53) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| Hydrochloric Acid SCHEMBL538324 | 0.90 | EPHX1 (0.63) | EPHX1PARP1HDAC4ALDH1A1 | |
| SCHEMBL12072636 | 0.88 | EPHX1 (0.57) | EPHX1HSD11B1CYP2C9USP30PARP1 | |
| SCHEMBL15655102 | 0.88 | EPHX1 (0.57) | EPHX1HSD11B1CYP2C9USP30PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-2032559-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007138268-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275567-A1 | 2-HETEROCYCLOAMINO-4-IMIDAZOLYLPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | CCNI, MKI67, CDK2 | EPHX1 1627/4885HSD11B1 3047/4885CYP2C9 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.